Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N. Shukuya T, et al. Among authors: naito t. Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28. Cancer Sci. 2011. PMID: 21272159 Free article.
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N. Murakami H, et al. Among authors: naito t. Cancer Chemother Pharmacol. 2012 Apr;69(4):891-9. doi: 10.1007/s00280-011-1738-1. Epub 2011 Nov 10. Cancer Chemother Pharmacol. 2012. PMID: 22071596 Clinical Trial.
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Kiyota H, Okamoto I, Takeda M, Daga H, Naito T, Miyazaki M, Okada H, Hayashi H, Tanaka K, Terashima M, Azuma K, Murakami H, Takeda K, Yamamoto N, Nakagawa K. Kiyota H, et al. Among authors: naito t. Cancer Chemother Pharmacol. 2013 Apr;71(4):859-65. doi: 10.1007/s00280-013-2077-1. Epub 2013 Jan 20. Cancer Chemother Pharmacol. 2013. PMID: 23334261 Clinical Trial.
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku N. Yamamoto N, et al. Among authors: naito t. Ann Oncol. 2013 Jun;24(6):1653-9. doi: 10.1093/annonc/mdt014. Epub 2013 Feb 14. Ann Oncol. 2013. PMID: 23413279 Free article. Clinical Trial.
1,790 results